© 2019 AAVANTI Biotherapeutics & AAVANTI, LLC


AAVANTIBio is a biotechnology company developing gene therapy for the debilitating neuromuscular disease known as Friedreich’s Ataxia (FA).

After working for several years to research the disease and getting to meet some of the amazing members of the FA community, founders Dr. Barry Byrne and Dr. Manuela Corti decided that they wanted to take their research to the next level.  AAVANTIBio was founded in 2017 and is driven by Dr. Byrne’s and Dr. Corti’s vision to create the first effective treatment for FA.